A bit more I left out... " These data further support Amplia’s...

A bit more I left out...
" These data further support Amplia’s view that FAK plays a critical role in the pathology of many fibrotic
diseases. The Company has now demonstrated anti-fibrotic activity for its FAK inhibitors in animal
models of lung fibrosis and NASH and in a range of in vitro studies. On the back of these positive data,
Amplia intends to conduct further exploratory, non-clinical studies evaluating the use of AMP886 and
AMP945 as potential treatments for liver fibrosis and other fibrotic diseases. Data from these studies
are expected to support Amplia’s future development and partnering programs.
“It is very encouraging to see such compelling data from using AMP886 and AMP945 in an industryrecognised model of NASH. We look forward to further exploring these promising findings as we
continue to build the dossier of non-clinical data for our FAK inhibitors.” said John Lambert, CEO of
Amplia. “Having completed dosing in our Phase 1 trial of AMP945 this month, our primary focus
remains on progressing AMP945 into Phase 2 clinical trials for pancreatic cancer and lung fibrosis.
However, in parallel, as we have communicated previously, we will continue to expand our data set
looking at other potential commercial opportunities.”